CHARM Investigators and Committees

Author PubWeight™ 33.82^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.	Lancet	2003	9.98
2	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.	Lancet	2003	8.12
3	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.	Lancet	2003	6.55
4	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.	Lancet	2003	4.99
5	Albuminuria in chronic heart failure: prevalence and prognostic importance.	Lancet	2009	2.79
6	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme.	Eur J Heart Fail	2010	1.00
7	Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.	Heart	2006	0.94
8	Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.	Eur J Heart Fail	2007	0.80
9	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes.	Cardiovasc Drugs Ther	2017	0.75